2-(甲基磺酰)苯磺酰氯化物 | 89265-35-0

• 物质功能分类: 化学试剂 - 有机试剂 - 磺酰卤化物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(甲基磺酰)苯磺酰氯化物
• 中文别名: 2-甲基磺酰苯磺酰氯；2-甲基磺酰基苯磺酰氯
• 英文名称: 2-Methanesulfonyl-benzenesulfonyl chloride
• 英文别名: 2-(methylsulfonyl)benzenesulfonyl chloride；2-methanesulphonylbenzenesulphonyl chloride；2-methylsulfonylbenzenesulfonyl chloride
• CAS: 89265-35-0
• 化学式: C₇H₇ClO₄S₂
• mdl: MFCD00216493
• 分子量: 254.715
• InChiKey: XPJTUCSESGEMOI-UHFFFAOYSA-N

物化性质

• 熔点：
  133-138 °C
• 沸点：
  442.0±37.0 °C(Predicted)
• 密度：
  1.4936 (estimate)
• 稳定性/保质期：
  按规定使用和贮存的不会分解，应避开氧化物、水分和碱。

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  85
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  8
• 危险品标志：
  Xi,C
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2904909090
• 包装等级：
  II
• 危险类别：
  8
• 危险品运输编号：
  UN3261
• 储存条件：
  在干燥、阴凉且密闭的环境中，并建议存放于惰性气体中。

SDS

Name:	2-Methylsulphonylbenzenesulphonyl chloride 95+% Material Safety Data Sheet
Synonym:
CAS:	89265-35-0

Section 1 - Chemical Product MSDS Name:2-Methylsulphonylbenzenesulphonyl chloride 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
89265-35-0	2-methylsulphonylbenzenesulphonyl chlo	95%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. May cause digestive tract disturbances. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse. Remove contaminated clothing and shoes.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Keep containers tightly closed.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 89265-35-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystals
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 136.00 - 137.00 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H7ClO4S2
Molecular Weight: 254.71

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stability unknown.
Conditions to Avoid:
Incompatible materials, strong oxidants.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Irritating and toxic fumes and gases.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 89265-35-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-methylsulphonylbenzenesulphonyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 37/39 Wear suitable gloves and eye/face
protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 89265-35-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 89265-35-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 89265-35-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(甲基磺酰)苯磺酰氯化物 在 lithium aluminium tetrahydride 、 二甲基二硫 、 sodium thiomethoxide 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 反应 21.0h， 生成 2-(Methylsulfonyl)phenyl disulfide
  参考文献：
  名称：

  New and More Potent Antifungal Disulfides

  摘要：

  根据早前一篇论文中描述的设计原则，已经制备并对抗黑曲霉和黄曲霉进行了测试的一系列取代芳基甲基二硫化物。甲基对硝基苯基二硫化物比真菌毒性天然产物(CH3SCH2S)2更强效（数量级更高）。有了目前的理论基础，人们可以预期哪种Polycarpamine是一种有效的抗真菌剂。

  DOI：

  10.1071/ch99139
• 作为产物：
  描述：

  2-氯苯基甲基砜 在 氯 、 溶剂黄146 、 potassium hydroxide 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.5h， 生成 2-(甲基磺酰)苯磺酰氯化物
  参考文献：
  名称：

  大规模制备2-（甲磺酰基）苯磺酰氯的研制

  摘要：

  描述了一种实用且可扩展的方法，用于制备2-（甲磺酰基）苯磺酰氯，这是用于合成几种候选药物的关键组成部分。该材料是通过高效的四步法从廉价的1,2-二氯苯和甲硫醇制备的，该方法已在多千克规模上得到证明，总产率为32％，化学纯度> 98％。

  DOI：

  10.1021/op2002744

文献信息

• Sulfonamides having antiangiogenic and anticancer activity
  申请人：——

  公开号：US20040157836A1

  公开（公告）日：2004-08-12

  Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.

  描述了具有蛋氨酸氨基肽酶-2抑制剂（MetAP2）的化合物。还描述了包括这些化合物的药物组合物、使用这些化合物的治疗方法、抑制血管生成的方法以及治疗癌症的方法。
• Aminoguanidines and alkoxyguanidines as protease inhibitors
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US06235778B1

  公开（公告）日：2001-05-22

  Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: wherein X is O or NR9 and R114 R4, R6-R9, R11, R12, Ra, Rb, Rc, Y, Z, n and mare set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

  氨基胍和烷氧基胍化合物，包括以下式的化合物： 其中X为O或NR9，R1、R4、R6-R9、R11、R12、Ra、Rb、Rc、Y、Z、n和m如规范中所述，以及其水合物、溶剂合物或药用可接受的盐，能够抑制蛋白酶酶，如凝血酶。还描述了制备上述式的化合物的方法。本发明的新化合物是蛋白酶的有效抑制剂，特别是类似胰蛋白酶的丝氨酸蛋白酶，如胰蛋白酶、凝血酶、纤溶酶和Xa因子。其中某些化合物通过直接、选择性地抑制凝血酶表现出抗血栓活性，或者是用于形成具有抗血栓活性的化合物的中间体。该发明包括一种用于在哺乳动物中抑制血小板丢失、抑制血小板聚集物形成、抑制纤维蛋白形成、抑制血栓形成和抑制栓塞形成的组合物，包括一种本发明的化合物在药学上可接受的载体中。本发明的化合物的其他用途是作为抗凝剂，嵌入或物理连接到用于制造用于血液采集、血液循环和血液储存的器械中的材料中，如导管、血液透析机、血液采集注射器和管道、血管内支架。
• Sulfur containing compounds
  申请人：——

  公开号：US20030220524A1

  公开（公告）日：2003-11-27

  This invention is directed to novel and known stufur containing compounds and pharmaceutically acceptable salts thereof that have utility as antifungals and as antiproliferative agents against mammalian cells, in particular cancer cells and most particularly leukemia-derived cells. The invention provides a method for synthesizing certain of the sulfur containing compounds that is more efficient than previously known methods.

  这项发明涉及新颖且已知的含有硫的化合物以及具有抗真菌活性和作为哺乳动物细胞，特别是癌细胞，尤其是白血病来源细胞的抗增殖剂的药用可接受盐。发明提供了一种合成某些含硫化合物的方法，该方法比先前已知的方法更有效。
• Bis-Acylated Hydroxylamine Derivatives
  申请人：Toscano John P.

  公开号：US20110136827A1

  公开（公告）日：2011-06-09

  The invention provides certain bis-acylated hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.

  这项发明提供了某些双酰化羟胺衍生物化合物，包括这些化合物的药物组合物和试剂盒，以及使用这些化合物或药物组合物的方法。具体而言，该发明提供了使用这些化合物或药物组合物治疗、预防或延缓疾病或病况发生和/或发展的方法。在某些实施例中，疾病或病况可选自心血管疾病、缺血、再灌注损伤、癌症疾病、肺动脉高压和对亚硝酰治疗有反应的病况。
• [EN] AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS<br/>[FR] SPIRODÉRIVÉS AZACYCLIQUES EN TANT QU'INHIBITEURS DE LA HSL
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010130665A1

  公开（公告）日：2010-11-18

  Compounds of formula (I) as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions, wherein n, m, A, R1 and R2 have the significance given in claim 1. The compounds are useful as HSL inhibitors for the treatment of diabetes dyslipidemia, atherosclerosis and obesity.

  式（I）的化合物及其药学上可接受的盐可以用作药物组合物的形式，其中n、m、A、R1和R2具有权利要求1中给出的含义。这些化合物可用作HSL抑制剂，用于治疗糖尿病脂质代谢紊乱、动脉粥样硬化和肥胖症。